SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing high volatility following its latest quarterly financial update, where investors are debating the company's shift from an EV manufacturer toward an AI and robotics-focused ecosystem. While the community remains deeply polarizedwith bulls emphasizing long-term innovation in autonomous driving and humanoid robots, and bears scrutinizing capital expenditures, margin reliance on one-time items, and delayed delivery timelinesthe stock continues to be a central battleground for options traders.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying to decade-long highs on extreme volume, driven by investor optimism surrounding potential hyperscaler partnerships and recent management commentary confirming orders linked to the optical connectivity sector. While the community is aggressively debating whether this surge represents a long-term revaluation or a speculative short squeeze, bulls are pointing to the company's active semiconductor manufacturing ramp as a catalyst to hold firm against short sellers.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as a sharp post-earnings sell-off sparks intense debate over the sustainability of SaaS valuations and the impact of geopolitical headwinds on enterprise software demand. While bulls highlight strong AI momentum and revenue growth as a buying opportunity, many in the community are debating whether the sector is undergoing a fundamental re-rating or if the market is overreacting to margin pressure and cautious guidance.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery shareholders are preparing for a pivotal vote on the proposed $110 billion merger with Paramount Skydance, an event that has sparked significant community debate regarding executive compensation packages and the potential impact on media competition. While investors are navigating the implications of a lucrative cash premium against concerns from industry creators, the conversation remains hyper-focused on whether this massive consolidation will successfully reshape the streaming landscape.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing massive volatility and a sharp downward correction as investors react to the company moving up its earnings date, sparking intense debate over a potential share dilution or institutional exit. The community is actively locked in a heated standoff between traders who view the recent parabolic surge as a classic pump-and-dump bubble that has finally burst and those looking for a technical bounce.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is under pressure as market participants debate the stock's future following a soft financial outlook and the ongoing search for a permanent CEO. Investors are actively discussing the impact of rising tariffs and increased competition in the athletic wear space, while some community members view the current valuation as a potential long-term entry point despite the prevailing skepticism.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is currently trending as investors weigh its engineering and execution risks against the broader supply chain challenges faced by peers like OKLO. While the stock has attracted momentum following recent DOE-related developments and institutional interest, community sentiment remains split between long-term bulls positioning for future nuclear infrastructure and skeptics questioning the current valuation and timeline to commercial scale.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is gaining momentum as community members highlight its expansion into a multi-chain "brandcoin" ecosystem featuring tangible products like energy drinks, spice, and apparel. Supporters are actively encouraging others to "lock in" and participate in the project's grassroots, IRL-focused initiatives, framing it as a unique, community-driven opportunity within the crypto space.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF is trending as investors grapple with a significant "SaaSpocalypse" narrative, where fears of AI-driven disruption and headcount reductions are weighing heavily on the enterprise software complex. While some market participants see this as a brutal structural repricing, community sentiment is highly polarized between those viewing current levels as a generational buying opportunity and others bracing for further volatility amidst ongoing margin concerns and institutional rotation out of SaaS.

United States Brent Oil Fund LP - Units

United States Commodity Funds LLC - United States Brent Crude Oil Fund

BNO is trending as geopolitical tensions in the Middle East and concerns over supply chain stability in the Strait of Hormuz keep oil volatility high. The community is actively debating the credibility of peace talks, with many traders betting on supply shocks while monitoring conflicting reports about ceasefire deals and regional military developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks.</li><li>Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.</li><li>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co.</li></ul>Shares of Novo Nordisk (NVO) saw increased retail chatter on Tuesday after the company announced the availability of its higher dose Wegovy injection across the U.S.On Stocktwits, retail sentiment around NVO stock stayed within the ‘neutral’ territory over the past 24 hours. Retail chatter around the stock jumped 136% over the same time frame.A Stocktwits user said that NVO stock remains “stubbornly undervalued.”<stembedurl>https://www.stocktwits.com/Johnnytwofour2/message/649581803</stembedurl>Another sounded hopes for a big move.<stembedurl>https://www.stocktwits.com/jonztown/message/649554573</stembedurl>The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies, including Novo’s own NovoCare Pharmacy and select telehealth providers, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-hd-available-now-nationwide-302735677.html">said</a>. The higher dose delivers the highest weight loss of any Wegovy injection to date. &nbsp;<h2 class="st-heading-2">Wegovy HD Approval</h2>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks as compared to 38% amongst those taking placebo.Prior to its approval, the highest approved dose of Wegovy injectable for weight loss was 2.4 mg.Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.“Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing and Patient Solutions at Novo Nordisk.<h2 class="st-heading-2">Novo Outlook</h2>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co (LLY).However, the company now expects its adjusted sales growth for 2026 to be down 5% to 13% at constant exchange rates, owing to lower realised prices and competition, among other factors.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-reports-nearly-double-its-market-cap-in-assets/cZJJwKlRIpM">Hyperscale Data Reports $102 Million In Assets, Nearly Double Its Market Cap</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.

Equity

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.


<ul class="summary-bullets"><li>Novo Nordisk states that Wegovy HD in a single-dose pen is expected to be available in April 2026.</li><li>Wegovy injectable was available in weekly doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg until now.</li><li>Novo Nordisk added that Wegovy 7.2 mg has already been approved in the U.K. and the European Union as three 2.4 mg doses per week.</li></ul>Novo Nordisk AS (NVO) on Thursday said the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a higher-dose version of its blockbuster weight-loss drug Wegovy, expanding options for patients seeking greater weight reduction.The company stated that Wegovy HD, a once-weekly injectable semaglutide at 7.2 mg, has received FDA accelerated approval based on results from the STEP UP trial program.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Thursday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">When Will Wegovy HD Be Available?</h2>Novo Nordisk stated that Wegovy HD in a single-dose pen is expected to be available in April 2026. Wegovy injectable was available in weekly doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg until now.“The FDA awarded a Commissioner’s National Priority Voucher for Wegovy HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the U.S.,” the company stated.Novo Nordisk added that Wegovy 7.2 mg has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvo-stock-is-rising-premarket-what-is-wegovy-news-driving-novo-nordisk-shares/cmUlo6aR4BT">already been approved</a> in the U.K. and the European Union as three 2.4 mg doses per week. It added that the regulatory decisions in the two markets for the single-dose pen are expected in the second half of 2026.<h2 class="st-heading-2">STEP UP Trial Shows Stronger Weight Loss</h2>Novo Nordisk stated that Wegovy HD’s accelerated approval by the FDA was based on a 72-week study that showed an average weight loss of about 20.7% in patients.The company added that nearly one in three patients receiving Wegovy HD experienced a 25% or greater weight loss.In the STEP UP type 2 diabetes trial, the company said participants demonstrated a mean weight loss of 14.1%, while about one in five patients experienced a weight loss of 20% or more.<h2 class="st-heading-2">Intensifying Competition</h2>Novo Nordisk’s launch of Wegovy HD follows CEO Mike Doustdar's warning of pricing headwinds in 2026 amid an increasingly competitive market.The Dutch company expects its 2026 sales to decline between 5% and 13% in constant-currency terms.“However, we are very encouraged by the promising early uptake from the U.S. launch of Wegovy pill, and we remain confident in our ability to drive volume growth over the coming years,” Doustdar added.Novo Nordisk rival Eli Lilly &amp; Co. (LLY) expects fiscal year 2026 revenue to rise between 23% and 28%, highlighting a divergence in the outlooks of the two companies this year.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 28% year-to-date and 54% over the past 12 months. The VanEck Pharmaceutical ETF (PPH) is up 9% over the past 12 months, while the Putnam Focused Large Cap Value ETF (PVAL) is up 20%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-american-rebel-stock-falling-today/cZ3aNN7RIhO">American Rebel Shares Sink More Than 40% — What's Driving The Plunge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy

The company stated that Wegovy HD received the FDA’s accelerated approval based on results from the STEP UP trial.

<ul class="summary-bullets"><li>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo.</li><li>The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.</li><li>The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator.</li></ul>Novo Nordisk AS’s (NVO) deal with Hims &amp; Hers Health Inc. (HIMS) has turned Wall Street bullish on both companies, with analysts stating that it helps them in dealing with a commercial headwind and removes a litigation risk from the equation.According to TheFly, analysts at BMO Capital noted that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">Novo Nordisk-Hims deal</a> to sell branded GLP-1 is a significant step forward in helping the Ozempic maker address a commercial headwind.The firm maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were down about 1% in Tuesday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up nearly 5% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">Why Are Analysts Bullish On HIMS?</h2>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator. BofA sees the risk-to-reward ratio as balanced now following the deal.Deutsche Bank also hiked its price target for HIMS to $28 from $25, implying an upside of more than 26% from Monday’s closing price. The firm cited the Novo deal for its price target hike, while keeping a ‘Hold’ rating on the HIMS stock.<h2 class="st-heading-2">What Did Novo, Hims Agree On?</h2>Hims and Novo Nordisk announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered. It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are covered.It added that these Ozempic and Wegovy offerings will be made available on its platform later this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user on Stocktwits believes selling HIMS stock at this point will be one of the “biggest mistakes” of their life.&nbsp;<stembedurl>https://stocktwits.com/TradeOrGoHome/message/647084706</stembedurl>Another user stated that every dip in the NVO stock is a “gift.”<stembedurl>https://stocktwits.com/King_of_the_bagholders/message/647086431</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 22% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 32%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-war-hegseth-most-intense-day-of-strikes-iranian-leaders-scrambling/cZdoAnzRI75">Iran War: Defense Secretary Hegseth Warns Of ‘Most Intense’ Strikes, Says The Middle East Country Is ‘Badly Losing’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

<ul class="summary-bullets"><li>Hims &amp; Hers said that existing patients will have the opportunity to transition to FDA-approved medicines when their providers deem it clinically appropriate.</li><li>The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered.</li><li>It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) surged more than 52% in Monday’s pre-market trading after Novo Nordisk A/S (NVO) partnered with the telehealth platform to offer Ozempic as well as Wegovy at affordable self-pay prices and dropped its patent infringement lawsuit against the company.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers, the company said.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 2% in Monday’s opening trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up around 39% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">What Does The Agreement Include?</h2>Hims &amp; Hers stated that the Ozempic and Wegovy offerings will be made available on its platform later this month.This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.Over the coming months, Hims &amp; Hers will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, the company will help support a smooth transition to these medications, the company said.<h2 class="st-heading-2">Novo’s Allegations</h2>In&nbsp;February this year, Novo had sued Hims &amp; Hers,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">stating</a> that the latter is duping consumers and healthcare professionals about the clinical benefits and safety of these unapproved drugs.The U.S. Food and Drug Administration (FDA) also warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 33%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">ImmunityBio Resubmits Supplemental Biologics License Application To FDA For Ankitva — IBRX Stock Declines Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

<ul class="summary-bullets"><li>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements when compared to placebo on key secondary endpoints.</li><li>Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, compared to 2% in the placebo group.</li><li>The company’s Chief Scientific Officer, Martin Holst Lange, added that Novo Nordisk is looking forward to reporting data from a global trial with UBT251 next year.</li></ul>Novo Nordisk AS (NVO) on Tuesday announced that its phase 2 clinical trial of a new obesity drug in China has shown successful results.Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.However,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> declined nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">UBT251 Trial Results Show Significant Improvements</h2>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements compared with placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids.The trial investigated the safety and efficacy of UBT251 at doses of 2 mg, 4 mg, and 6 mg.Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, or about 17.5 kg, compared to 2% or 1.6kg in the placebo group after 24 weeks of treatment.“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange.Lange added that the company is looking forward to reporting data from a global trial with UBT251 next year.<h2 class="st-heading-2">Why Is NVO Stock Declining Pre-Market?</h2>Novo Nordisk shares continued to decline in Tuesday’s pre-market session. This is after a fall of more than 16% on Monday, following the company's announcement that CagriSema demonstrated 23% weight loss in people with obesity in the Redefine 4 trial,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC">failing to meet</a> its primary endpoint.According to TheFly, analysts at JPMorgan downgraded Novo Nordisk to ‘Neutral’ from ‘Overweight’, calling the CagriSema results “disappointing.”The firm also further reduced its CagriSema forecasts by up to 63% through 2030, expecting a more challenging uptake for the product given its "inferiority" to Eli Lilly and Co.’s (LLY) Zepbound.Analysts at Kepler Cheuvreux downgraded NVO to ‘Hold’ from ‘Buy’ and stated that the company’s Redefine 4 study was a “major negative surprise.”Nordea analysts also downgraded Novo Nordisk to ‘Hold’ from ‘Buy’, with the firm citing a lack of near-term catalysts following Monday’s obesity study results.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status/cZRtw5dR4yV">Is Microsoft Down? MSFT 365 Error Reports Spike On Downdetector, Company Says It Is Investigating The Issue</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

<ul class="summary-bullets"><li>The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.</li><li>People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.</li><li>When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.</li></ul>Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> trended in the ‘extremely bearish’ territory at the time of writing.<h2 class="st-heading-2">CagriSema Fails To Match Tirzepatide In Effectiveness</h2>Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.<h2 class="st-heading-2">Who Is CagriSema Aimed At?</h2>CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-replicate-most-tariffs-after-supreme-court-ruling-goldman-sachs/cZRNfSqR4xV">Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

<ul class="summary-bullets"><li>It is unclear what the company intends to charge for the vials, the report said.</li><li>Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats. &nbsp;</li><li>Novo also has a pill version of its obesity drug called Wegovy pill launched in early January to regain its slipping market share in the obesity segment.</li></ul>Danish drugmaker Novo Nordisk (NVO) is reportedly looking to sell its injectable Wegovy in vials in a move that mirrors rival Eli Lilly and Company (LLY).Bloomberg<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials?srnd=homepage-americas"> reported </a>on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year, followed by launches in other countries.It is unclear what the company intends to charge for the vials, the report said. &nbsp;<h2 class="st-heading-2">Wegovy Upgrade</h2>Presently, Novo sells Wegovy in injector pens. Unlike Novo, Eli Lilly sells its obesity drug Zepbound in both injector pen and vial formats. The vials were introduced about two years ago to increase supply, improve access, and offer a lower-cost option.Injector pens are the standard auto-injector devices, often preferred for ease of use as they do not require manual drawing of medication. Meanwhile, vials require the use of a separate needle and syringe to draw up the medication.Novo also has a pill version of its obesity drug called Wegovy pill launched in early January as it pushes to regain its slipping market share in the obesity segment.<h2 class="st-heading-2">Novo’s Disappointing Outlook</h2>Novo now <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-shares-tumble-on-q4-miss-weak-sales-forecast/cZbi6tLR4m0">expects</a> adjusted sales to fall between 5% and 13% in fiscal 2026, and operating profit could decline by up to 13%.The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S. while issuing the guidance earlier this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock stayed within ‘bearish’ territory over the past 24 hours, while message volume fell from ‘extremely high’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-rallies-as-insiders-buy-company-shares/cZb6pAeR4Ah">ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly 

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

<ul class="summary-bullets"><li>The FDA stated that the totality of the claims made by Novo in the ad misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.</li><li>The agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments.</li><li>The FDA has sought a reply from Novo within 15 working days from the date of receipt.</li></ul>A television advertisement by Novo Nordisk A/S (NVO) for its obesity pill Wegovy has been flagged as “misleading” by the U.S. Food and Drug Administration (FDA).According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy. It added that this violates the distribution provisions of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 8% in Monday’s opening trade, but pared some of the gains to hover nearly 4% higher at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” said Liz Skrbkova, Novo’s head of U.S. media and stakeholder relations, according to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/09/fda-novo-nordisk-wegovy-tv-ad.html">report</a>.<h2 class="st-heading-2">What Is The FDA Objecting To?</h2>The FDA stated that the totality of the claims made by Novo in the TV advertisement misleadingly suggests that, because of its pill form, Wegovy offers an advancement or improvement over other currently approved GLP-1 treatments for weight loss.“Specifically, these claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss,” the FDA stated in its letter.In particular, the agency pointed to terms such as “live lighter” and “a way forward” to argue that the Novo advertisement misleadingly implies greater weight loss than other currently approved GLP-1 treatments, even though this has not yet been demonstrated.Beyond this, the FDA stated that the advertisement implies additional benefits such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the pill as a solution to broader life problems rather than just a specific physical condition.The agency has sought a reply from Novo within 15 working days of receipt.<h2 class="st-heading-2">Novo’s Legal Battle With Hims &amp; Hers</h2>The FDA letter comes amid Novo’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">legal battle</a> with Hims &amp; Hers Health Inc. (HIMS). The Wegovy-maker sued Hims &amp; Hers, calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process,” the company said.Last week, the FDA warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 4% year-to-date and 43% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

<ul class="summary-bullets"><li>Novo also stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.</li><li>Last week, the U.S. Food and Drug Administration warned of a crackdown last week on GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs.</li><li>Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.</li></ul>Novo Nordisk A/S (NVO) on Monday stated that it has filed a lawsuit against Hims &amp; Hers Health Inc. (HIMS), calling for a permanent ban on the company’s sales of unapproved, compounded drugs that infringe its patents.Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 5% in Monday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were down more than 19% at the time of writing. Retail sentiment around the NVO stock trended in the ‘bullish’ territory on the platform.<h2 class="st-heading-2">Novo Accuses HIMS Of Duping Consumers</h2>Novo stated that Hims &amp; Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold standard review process – that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective,” said Novo Nordisk’s senior vice president, Group General Counsel, Global Legal, IP and Security, John F. Kuckelman.The company also announced a share repurchase program on Monday of up to DKK 15 billion ($2.4 billion to be executed during a 12-month period beginning Feb. 4, 2026.<h2 class="st-heading-2">FDA Warns Of Crackdown On Compounded GLP-1 Drugs&nbsp;</h2>Last week, the U.S. Food and Drug Administration (FDA) warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<h2 class="st-heading-2">Analysts Warn Of Sales Hit</h2>The FDA crackdown has resulted in sharp price target cuts from analysts, according to TheFly.Analysts at Citi warned that Hims &amp; Hers’ launch of the compounded pill version of Wegovy is “risky and aggressive,” and that it brings more legal risk to the company.The firm trimmed its price target for Hims &amp; Hers to $16.5 from $30, while maintaining a ‘Sell’ rating. Citi analysts stated that the new price target factors in a 25% bear case probability of Hims &amp; Hers losing all weight loss drug sales, a 60% base case probability of the company losing half of the sales, and a 15% bull case probability of limited GLP-1 downside from the legal challenges.Analysts at BofA also lowered their price target for the HIMS stock to $21 from $26, while keeping an ‘Underperform’ rating. The firm noted that the FDA did not make a distinction between oral and injectable products in its crackdown warning.This leads BofA analysts to believe that the FDA’s crackdown could extend beyond APIs for oral GLP-1 treatment and include APIs for injectable semaglutide as well. The firm believes this adds a new risk to Hims' injectable GLP-1 franchise.<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers</a> trended in the ‘extremely bullish’ territory at the time of writing.One user pointed out that the company’s legal battle with Novo hasn’t even started yet.<stembedurl>https://stocktwits.com/weqwewqeq1111/message/644437840</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 29%.$1 = DKK 6.30Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pgy-stock-rising-today-ahead-of-ai-lenders-q4-earnings/cZbHxXpR48v">PGY Stock Pops Pre-Earnings: Wall Street Bets On Pagaya’s AI-Powered Lending Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

PVAL
Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PVAL News

PVALPutnam ETF Trust - Putnam Focused Large Cap Value ETF